| Literature DB >> 8445043 |
C Mathiot1, J L Teillaud, M Elmalek, V Mosseri, L Euller-Ziegler, A Daragon, B Grosbois, J L Michaux, T Facon, J F Bernard.
Abstract
CD16, the type III receptor for IgG, is expressed on neutrophils, natural killer cells, and some T lymphocytes, mast cells, and activated monocytes but not on cells of the B-lymphocyte lineage including plasma cells. It is also produced in a soluble form found in serum. We analyzed sera from 165 multiple-myeloma patients, 29 patients with monoclonal gammopathies of unknown significance, and 20 normal disease-free donors. We found that the level of soluble CD16 was significantly decreased in sera from patients with multiple myeloma compared to sera from healthy and monoclonal gammopathies of unknown significance donors (P = 0.0001). In addition, a stage-dependent decrease in soluble CD16 was observed, with a highly significant difference (P = 0.004) between stage I and stage II+III myeloma patients. The correlation between the myeloma stage and the serum level of soluble CD16, which is related to the host response, was found to be more sensitive than that of beta 2-microglobulin, which reflects the tumor burden. The concomitant evaluation of the serum levels of these two markers allows better staging and therefore has a more precise prognostic value.Entities:
Mesh：
Substances：
Year: 1993 PMID： 8445043 DOI： 10.1007/bf00920634
Source DB: PubMed Journal: J Clin Immunol ISSN： 0271-9142 Impact factor: 8.317